Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $23.67.

ACRV has been the topic of a number of recent analyst reports. Cantor Fitzgerald assumed coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating on the stock. KeyCorp assumed coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating for the company.

Institutional Investors Weigh In On Acrivon Therapeutics

Hedge funds have recently made changes to their positions in the company. Barclays PLC lifted its position in Acrivon Therapeutics by 51.2% during the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after buying an additional 11,273 shares during the period. State Street Corp increased its stake in shares of Acrivon Therapeutics by 26.4% in the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after acquiring an additional 47,233 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after acquiring an additional 28,748 shares during the period. Exome Asset Management LLC bought a new stake in Acrivon Therapeutics during the third quarter worth about $817,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Acrivon Therapeutics in the fourth quarter worth about $40,000. 71.62% of the stock is currently owned by institutional investors.

Acrivon Therapeutics Price Performance

NASDAQ ACRV opened at $5.50 on Tuesday. Acrivon Therapeutics has a 1 year low of $4.69 and a 1 year high of $11.90. The stock has a market capitalization of $171.25 million, a PE ratio of -2.04 and a beta of 0.85. The business’s 50-day moving average is $5.59 and its 200 day moving average is $6.77.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.